Nattokinase Case Studies in Cancer Patients
There are no published case studies specifically documenting nattokinase use in individual cancer patients, but recent preclinical research demonstrates promising tumor microenvironment modulation effects that warrant attention.
Current Evidence Base
The available evidence consists entirely of preclinical laboratory and animal studies rather than human case reports or case series. The most relevant research includes:
Tumor Microenvironment Remodeling Studies
The most compelling recent work shows nattokinase can enhance CAR-T cell therapy efficacy in solid tumors 1, 2. These 2023-2025 studies demonstrate that nattokinase degrades extracellular matrix (ECM) components—particularly fibronectin—and inhibits cancer-associated fibroblasts (CAFs). This remodeling:
- Decreases tumor stiffness and enhances perfusion
- Alleviates hypoxia within tumors
- Improves CAR-T cell infiltration into solid tumors
- Enhances chemotherapy and radiotherapy effectiveness by improving drug delivery 2
Animal Model Studies
A 2019 study showed nattokinase crude extract (NCE) improved survival rates by 31% in hepatocellular carcinoma (HCC) mouse models 3. The treatment:
- Decreased ascites formation
- Reduced tumor growth significantly
- Inhibited FOXM1 expression (a cancer proliferation marker)
- Reduced angiogenesis markers (CD31) and cancer stem cell markers (CD44, vimentin)
Drug Delivery Enhancement
Research from 2020 demonstrated that nattokinase-polysialic acid complexes can clear cancer-associated thrombus (CAT), which blocks both nanoparticle drug delivery and immune cell access to tumors 4. This approach enhanced doxorubicin liposome accumulation in tumors and improved anti-tumor activity.
Critical Limitations
No human case studies, case series, or clinical trials exist in the peer-reviewed literature. The evidence is entirely:
- In vitro cell culture experiments
- Mouse xenograft models
- Preclinical mechanistic studies
The ESPEN cancer nutrition guidelines 5 make no mention of nattokinase, focusing instead on established nutritional interventions like N-3 fatty acids for cancer cachexia.
Clinical Context
While nattokinase shows interesting preclinical mechanisms—particularly in modulating the physical tumor microenvironment to enhance other therapies—there is currently no evidence supporting its use in cancer patients outside of research protocols. The fibrinolytic properties that make it useful for cardiovascular applications 6, 7 may theoretically affect tumor-associated thrombosis, but this remains unproven in cancer patients.
Important Caveats
- Nattokinase has potent fibrinolytic activity, raising bleeding risk concerns in cancer patients (who often have thrombocytopenia or are on anticoagulants)
- No safety data exists for cancer patient populations
- No dosing information is available for oncologic applications
- Drug interactions with chemotherapy agents are unknown
The absence of human case studies reflects that nattokinase remains an experimental approach in oncology, confined to laboratory investigation.